PreciseDx

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

PreciseDx headquartered in New York, New York, United States, North America, operates in the Health Care sector. The company focuses on Health Care and has secured $251.8M in funding across 8 round(s). With a team of 1-10 employees, PreciseDx is actively contributing to advancements in Health Care. Their latest funding round, Series B - PreciseDx, raised $20.7M. Discover more about their projects, partnerships, and impact on our platform.